Trials / Recruiting
RecruitingNCT05753306
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
A Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This phase II clinical trial tests how well robotic cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with gastric cancer that has spread to the tissue that lines the wall of the abdominal cavity (peritoneum). Gastric cancer is the third leading cause of cancer related deaths worldwide and peritoneal metastasis are found in 30% of patients at time of diagnosis. Patients with peritoneal metastasis have poor survival rates. Traditional surgery is done with a large incision and has a high complication rate and longer hospital stays. Robot assisted (robotic) cytoreduction is a surgical option that uses small incisions and there is less risk of complications. HIPEC involves infusing heated chemotherapy into the abdominal cavity during surgery. Robotic cytoreduction together with HIPEC may improve recovery and decrease complications after surgery.
Conditions
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Metastatic Malignant Neoplasm in the Peritoneum
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin | Given via HIPEC |
| PROCEDURE | Computed Tomography | Undergo CT scan or PET/CT |
| PROCEDURE | Gastrectomy | Undergo robotic gastrectomy |
| PROCEDURE | Magnetic Resonance Imaging | Undergo MRI |
| PROCEDURE | Positron Emission Tomography | Undergo PE/CT |
| OTHER | Questionnaire Administration | Complete questionnaire |
| DRUG | Paclitaxel | Given via HIPEC |
| DRUG | Hyperthermic Intraperitoneal Chemotherapy | Undergo HIPEC |
Timeline
- Start date
- 2023-04-20
- Primary completion
- 2030-03-25
- Completion
- 2030-03-25
- First posted
- 2023-03-03
- Last updated
- 2026-04-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05753306. Inclusion in this directory is not an endorsement.